**Indications and effects of plasma transfusions in critically ill children**

**Oliver Karam1, Pierre Demaret2, Alison Shefler3, Stéphane Leteurtre4, Philip Spinella5, Simon Stanworth6, Marisa Tucci7, on behalf of the Canadian Critical Care Trials Group (CCCTG), Pediatric Acute Lung Injury and Sepsis Investigators (PALISI), BloodNet, and the PlasmaTV investigators8**

1Pediatric Intensive Care Unit, Geneva University Hospital, Geneva, Switzerland

2Pediatric Intensive Care Unit, CHC Liège, Liège, Belgium

3Pediatric Intensive Care Unit, Oxford University Hospitals, Oxford, UK

4Pediatric Intensive Care Unit, CHU Lille, Lille, France

5Pediatric Intensive Care Unit, St. Louis Children’s Hospital, St. Louis, MO, USA

6NHS Blood and Transplant, John Radcliffe Hospital, Oxford, UK

7Pediatric Intensive Care Unit, CHU Sainte-Justine, Montreal, Canada

8PlasmaTV investigators are listed in the acknowledgments

Corresponding author: Dr Oliver Karam, MD, MSc

Pediatric Intensive Care Unit

Geneva University Hospital

6 rue Willy Donzé

1211 Geneva

Switzerland

oliver.karam@hcuge.ch

**Contribution**:OK, PH, SS and MT initiated and designed the study. OK, PD, AS, PH, SS and MT contributed to the acquisition of the data. All authors contributed to the data analysis, the writing of the manuscript and approved the final version. The CCCTG and the BloodNet helped improve the study design and reviewed the manuscript. The PlasmaTV investigators collected the data and approved the final manuscript.

**Funding**: This study was funded by the Groupe Francophone de Réanimation et Urgences Pédiatriques (GFRUP) and the Marisa Sophie Research Foundation for Critically Ill Children.

**Running Title**: Plasma transfusions in critically ill children

**Descriptor number**: 4.11     Pediatric Critical Care

**Number of words**: Manuscript: 3049 words

**At a Glance Commentary:**

*Scientific Knowledge on the Subject*: Plasma transfusions are frequently prescribed for critically ill children, although most clinical uses of plasma are not evidence-based.

*What This Study Adds to the Field*: Our data indicate that a third of transfused patients were not bleeding and had no planned procedure. Furthermore, plasma transfusion only corrected coagulation tests for patients with severe coagulopathy.

# Abstract

**Rationale**: Plasma transfusions are frequently prescribed for critically ill children, although their indications lack strong evidence base.  Plasma transfusions are largely driven by physician conceptions of need and these are poorly documented in pediatric intensive care patients.

**Objective**: To identify patient characteristics and characterize indications leading to plasma transfusions in critically ill children and to assess the effect of plasma transfusions on coagulation tests.

**Methods**: Point-prevalence study in 101 pediatric intensive care units in 21 countries, on six pre-defined weeks. All critically ill children admitted to a participating unit were included if they received at least one plasma transfusion.

**Main results:** During the six study weeks, 13192 children were eligible among whom 443 (3.4%) receiving at least one plasma transfusion were included. The primary indications for plasma transfusion were critical bleeding in 22.3%, minor bleeding in 21.2%, planned surgery or procedure in 11.7%, and high risk of post-operative bleeding in 10.6%. No bleeding or planned procedures were reported in 34.1%. Prior to plasma transfusion, the median International Normalized Ratio (INR) and activated Partial Thromboplastin Time (aPTT) values were 1.5 and 48, respectively. After plasma transfusion, the median INR and aPTT changes were -0.2 and -5, respectively. Plasma transfusion significantly improved INR only in patients with a baseline INR >2.5.

**Conclusions**: A third of transfused patients were not bleeding and had no planned procedure. Additionally, in most patients, coagulation tests are not sensitive to increases in coagulation factors resulting from plasma transfusion. Studies assessing appropriate plasma transfusion strategies are urgently needed.

Abstract: 250 words

# Introduction

Although plasma transfusions are frequently prescribed worldwide, the indications for their use remain unclear. In 2011, 3,882,000 plasma units were transfused in the United States in adults and children (1). According to US pediatric health information administrative databases, nearly 3% of all recorded pediatric admissions receive a plasma transfusion during their hospital stay (2). In France, administration of plasma has increased by more than 40% over the last ten years, often in clinical situations where the biological and/or clinical criteria do not seem to justify its use (3). Experts recommend plasma transfusions mainly in the context of massive transfusion and in case of bleeding associated with documented abnormal coagulation tests(4, 5).

In massively bleeding patients, observational data suggest that early use of plasma and platelets seems to be associated with improved outcomes in patients with life-threatening bleeding (6). However, in a less critical clinical context, adult and pediatric epidemiological studies have shown an independent association between plasma transfusion and development of nosocomial infections (7, 8), acute respiratory distress syndrome (9-11), multiple organ failure (8, 11) and mortality (12). Therefore, it might seem important to determine when the benefits outweigh the side effects, especially as previous studies have already shown that plasma transfusions failed to correct mildly abnormal coagulation tests (13-15). There is no specific pediatric data on this issue. However, the increased morbidity associated with plasma transfusions in observational studies might be due to unrecognized biases, as plasma might be given to sicker patients.

Plasma transfusions are frequently administered to correct abnormal coagulation tests (16) which are often viewed as predicting a risk of bleeding although Segal et al have shown that abnormal coagulation tests are not associated with increased risk of bleeding in most procedures (17). In 2007, Lauzier et al reported that plasma transfusions were often administered to critically ill adults who were not bleeding and who did not required an invasive procedure/surgery (18). In 2011, Stanworth et al reported that half of the plasma transfused in the UK was given to non-bleeding patients (15).These practices are not in accordance with the guidelines for the use of frozen plasma published by expert committees (4, 5). This might lead to a significant waste, especially as blood availability is already a major concern.

There are few published reports of the reasons for plasma transfusion in children. A recent pediatric international survey showed an important heterogeneity in plasma transfusion thresholds and strategies (19), with two-thirds of responding pediatric critical care physicians stating that they prescribe plasma transfusions for non-bleeding critically ill children. This marked heterogeneity in plasma transfusion patterns might be due to the absence of randomized controlled trials (RCTs) that could guide plasma transfusion strategies (20).

This point-prevalence study is part of a larger undertaking that aims to design a RCT to address optimal plasma transfusion strategies in critically ill children (8, 19, 20). Our primary objectiveswere to identify the characteristics and clinical situations resulting in plasma transfusion and to evaluate changes in coagulation laboratory values resulting from the initial plasma transfusion in critically ill children.

# Methods

*Study sites and population*

This point-prevalence study is an international multicenter cross-sectional observational study carried out in 101 Pediatric Intensive Care Units (PICUs) in 21 countries. Clinical sites were recruited through several research networks including BloodNet of the Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI), the Canadian Critical Care Trials Group (CCCTG), the European Society of Pediatric Neonatal Intensive Care (ESPNIC), the UK Pediatric Intensive Care Society (PICS), the Groupe Francophone de Réanimation et Urgences Pédiatriques (GFRUP), and the Australian and New Zealand Intensive Care Society (ANZICS), as well as through personal contacts made by the study investigators. For each study site, six one-week periods were randomly predefined over six consecutive months (April to September 2014).  Within each week, screening was done and data were collected on 5 days (Monday to Friday, from midnight to midnight).

All critically ill children aged 3 days to 16 years old admitted to a participating PICU on one of the 30 study days were considered eligible. Any eligible patient for whom at least one plasma transfusion was administered on any study day was included unless one of the exclusion criteria (i.e. plasmapheresis and gestational age less than 37 weeks at the time of PICU admission) was present. If a patient was readmitted within 24 hours of PICU discharge, this was considered part of the same admission.

*Outcome definitions*

The *primary outcome* was the primary indication for the first plasma transfusion and the coagulation tests prior to that transfusion. We only considered plasma transfusions, but not cryoprecipitate, albumin, or infusions of specific coagulation factors.

Clinical indications were categorized as follows:

*A) Critical bleeding*: massive bleeding (transfusion of all blood products > 80 ml/kg within 24 hours), bleeding in specific sites (intra-cranial, intra-ocular, retroperitoneal, intra-spinal, pericardial, non-traumatic intra-articular);or bleeding requiring a surgical intervention or drainage (e.g. hemothorax requiring drainage) (21)

*B) Minor bleeding*: minor surgical bleeding (wound, drain, etc.) or minor non-surgical bleeding (endotracheal tube secretions, nasogastric tube, urine, etc.)

*C) Planned surgery or procedures* (central venous catheter, pleural drain, etc.)

*D) High risk of post-operative bleeding* (as defined by the intensivist)

*E) No bleeding, no planned procedure* (hypovolemia, abnormal coagulation tests, factor or component replacement, at high risk of bleeding due to non-surgical reasons, etc.)

The *secondary outcome* was the changes in coagulation tests that occurred after the first plasma transfusion.

We also collected data on the transfusion itself, such as the product that had been used [Fresh-Frozen Plasma (FFP), Frozen Plasma (FP), Mirasol-treated Plasma, Solvent/Detergent Plasma (SD plasma)] (22), the rate and volume of the transfusion.

Description and clinical outcome of the population was studied using daily Pediatric Logistic Organ Dysfunction (PELOD)-2 score (23), length of mechanical ventilation, PICU length of stay, and PICU mortality. Because the PELOD-2 score is predictive of mortality when measured on certain specific days, we collected patient data on days1 (first transfusion), 2, 5, 8, and 12 of PICU stay (24). Length of mechanical ventilation, PICU length of stay, and PICU mortality were censored 28 days after the end of the enrollment period.

*Ethics approval*

This study was approved by ethics committees or boards at all sites. Five centers (two in Canada, one in Denmark, Italy and Norway) required to obtain individual patient written consent. French and Belgian sites provided study information in the PICU waiting room, with an opt-out (or passive) consent. The ethics committees or boards of all other sites did not require individual consent.

*Sample size*

The sample size was calculated to attain a precision of ± 5% of the proportion of patients in whom plasma was transfused despite the fact they were non-bleeding and without planned invasive procedures. The estimated proportion was 34%, based on previously reported data in critically ill adults (18). Based on these assumptions, the study aimed to enroll 339 critically ill children who received at least one plasma transfusion.

*Statistical analysis*

Descriptive statistics are reported as mean ± standard deviation (SD), median and interquartile range (IQR), or proportions with their 95%CI.

We assessed the association between the indication for plasma transfusion and the different variables (demographic data, coagulation tests, clinical outcome measures) with a Pearson Chi-Square test (for dichotomous variables) and a one-way ANOVA test for continuous variables. We assessed the difference between coagulation test results drawn before and after plasma transfusion using the Wilcoxon signed rank test. Coagulation test cut-offs were determined incrementally, using the Wilcoxon signed rank test, by steps of 0.5 and 5 for International Normalized Ratio (INR) and activated partial thromboplastin time (aPTT), respectively. We also assessed the association between plasma transfusion dose and change in coagulation tests using a one-way ANOVA, after categorizing the doses. Correlations between non-normally distributed variables were assessed with Spearman’s correlation test.

All tests were 2-sided, with an alpha level of 0.05. All statistical analyses were performed with SPSS version 20 for Mac (SPSS, Chicago, IL, USA).

# Results

*Frequency and description of the population*

One hundred and one PICUs from 21 countries participated in this study, from April to September 2014. Fifty-six centers were in Europe, 35 in North America, 5 in Oceania, 3 in Asia, and 2 in South America. The median number of beds per PICU was 13 (IQR 10-22).

Over the 30 study days, 13,192 patients were admitted and hence eligible. Per PICU, the median number of patients already admitted at the beginning of a study week was 9 (IQR 5-13) and the median number of new admissions on each study day was 2 (IQR 1-3).

Only one patient was not enrolled because written consent was not obtained. Plasma transfusions were observed in 443 patients (3.4%, 95%CI 3.1-3.7). The median length of PICU stay prior to the first plasma transfusion was 1 day (IQR 0-5).

Table 1 describes the baseline characteristics of included patients. The median age and weight were 1 year (IQR 0.2-6.4) and 9.1 kg (IQR 4.0-21.0), respectively. 43% were males. The median PELOD-2 score was 7 (IQR 5-10).

The center which included the largest number of patients contributed 11.1% of the results. Fifteen centers (15/101, 14.8%) did not transfuse plasma during their six study weeks.

*Indications for plasma transfusion*

The primary indication for plasma transfusion was critical bleeding in 22.3% of patients (95%CI 18.7-26.5), minor bleeding in 21.2% (95%CI 17.78-25.3), planned surgery or procedure in 11.7% (95%CI 9.1-15.7), and high risk of post-operative bleeding in 10.6% (95%CI 8.0-14.0). No bleeding or planned procedures were reported in 34.1% of patients (95%CI 29.8-38.6) (Fig.1). Among the latter, 68.3% (95%CI 60.4-75.1) were transfused to correct abnormal coagulation tests, 13.2% (95%CI 8.7-19.6) were considered at high risk of bleeding due to their medical condition, 12.6% (95%CI 8.2-18.8) were transfused to treat hypovolemia, and 6.0% (95%CI 3.2-10.9) were transfused to replace losses (ascites, chylothorax or antithrombin deficiency).

Forty-eight patients received plasma while on Extracorporeal Life Support (ECLS); 12 of these (25%) received plasma for critical bleeding. Six (13%) received plasma as part of an ongoing trial (NCT01903863).

*Coagulation tests before plasma transfusion*

Coagulation tests were performed prior to the first plasma transfusion in 96.4% of the patients. Prothrombin Time (PT) was measured in seconds and in percentage in 59.1% and 23.3% of the patients, respectively. INR and aPTT were measured in 74.0% and 90.3% of patients, respectively. The median time between sampling for coagulation tests and initiation of plasma transfusion was 3.5 hours (IQR 1.7-6.5).

The median results for INR and aPTT were 1.5 (IQR 1.3-2.0) and 48 (IQR 36-75), respectively. Thirty percent of patients transfused were not bleeding, had no planned procedure, and had an INR < 1.5.

Thromboelastography (TEG) was performed in seven centers (located in three countries: Denmark, United Kingdom and USA) on 13 (2.9%) patients. Rotational Thromboelastometry (ROTEM) was performed in four centers (located in Belgium, France, Italy, and Switzerland) on 7 (1.6%).

*Plasma transfusions*

At the time of the first plasma transfusion, Fresh-Frozen Plasma was given to 75% of the patients, whereas Solvent/Detergent Plasma and Frozen Plasma were given in 14% and 6%, respectively. Physicians were not aware of the type of plasma in 5% of transfusions. The median dose of plasma was 11 ml/kg (IQR 9.7-15.1). Plasma was transfused over a median time of 60 minutes (IQR 30-104). The median dose and median transfusion rate were not significantly higher for patients with critical bleeding (p=0.10).

*Coagulation tests after plasma transfusion*

Coagulation tests were performed after the first plasma transfusion in 89.4% of patients. The median time between the end of the plasma transfusion and sampling for coagulation tests was 4.0 hours (IQR 1.7-8.2).

The median results for INR and aPTT were 1.4 (IQR 1.2-1.7) and 41 (IQR 33-59), respectively. The median INR and aPTT changes are -0.2 (IQR -0.4 to 0, n=281, p<0.001) and -5 (IQR -17 to 2, n=356, p<0.001), respectively (Fig. 2).

After plasma transfusions, TEG and ROTEM were performed in 7 (1.6%) and 4 (0.9%) patients, respectively.

Changes in INR and aPPT values compared to baseline are shown in Figures 3A and 3B. The median INR change after transfusion was -0.1 (IQR -0.3 to 0) for 273 children (83%) with a baseline INR value < 2.5 and -1.1 (IQR -2.0 to -0.4) for 55 children (17%) with a baseline INR value ≥ 2.5 (p<.0001). The median aPTT change after transfusion was -2 (IQR -7 to -3) for 249 children (62%) with a baseline aPTT value < 60 sec and -22 (IQR -44 to -5) for 151 children (38%) with a baseline aPTT value ≥ 60 sec (p<.0001).

*Effect of plasma dose*

Figure 4 shows how the plasma dose transfused modified INR and aPTT values according to baseline. A dose-response relationship was observed only in children with a baseline INR ≥ 2.5 (Spearman’s Rho coefficient -0.47, p<0.001).

*Clinical outcome*

Median length of mechanical ventilation was 5 days (IQR 1-16) and median PICU length of stay was 10 days (IQR 4-24) in our study population. Table 2 shows that there were no statistically significant variations according to the primary indication for plasma transfusion. PICU mortality was 26.9% (119/443, 95%CI 23-31).

# Discussion

In this large international observational study, we examined the indications of plasma transfusions in critically ill children and their effects on coagulation tests. We found that 34% of patients who receive plasma were neither bleeding nor being prepared for a procedure, whereas only 22% receive plasma for critical bleeding.

Clinically significant decrease in INR and aPTT values were only noted for INR values > 2.5 or aPTT values > 60 sec. These findings underscore that when the INR is only mildly prolonged, the assay is not sensitive to the increase in coagulation factors resulting from transfusion. It must be recognized that coagulation tests may not be the most appropriate measure of plasma transfusion efficacy, as they fail to predict bleeding (17). Unfortunately, alternative laboratory measures to better ascertain this do not exist at the present time.

In 2004, Dzik et al reported that the most common purpose of plasma transfusion in adults was to «prepare» a patient with an elevated INR for invasive procedures (16). In 2007, Lauzier et al also showed that plasma transfusions were often administered to critically ill adults who were not bleeding; 33.7% of plasma orders were for non-bleeding patients with no planned invasive procedures (18). Our study shows very similar results; 34.1% of patients transfused with plasma were not bleeding and had no planned invasive procedures.

The effect of plasma transfusions on coagulation tests has been described in adults. In 121 patients with moderately abnormal coagulation tests (INR < 1.85), the post-transfusion INR value decreased to below 1.1 in only 0.8% of this mixed surgical and medical intensive care patient population (13). In another study, Holland et al showed that plasma transfusion did not correct INR levels < 2.0-2.5 in 103 adult patients who received 174 transfusions (14). These studies demonstrate the inability of the INR to document the effect of plasma infusions at INR values commonly encountered in critical care patients. Similar results have also been reported by Stanworth et al (15). Our study shows that only severely abnormal coagulation tests are improved by plasma transfusions and that this association was non-linear. This is likely due to the exponential relationship between coagulation factor concentration and coagulation test results (25). Our results suggest that a mild to moderate elevation of the INR in a non-bleeding patient is not a worthwhile target for intervention.

Despite improvements in the management of blood products, some modeling suggests that blood availability could become a major concern in the next 5-10 years due to increasing demand in certain patient populations (26) which in turn justifies the rationalization of blood product (including plasma) transfusions. More specifically, in order to ensure the best use of blood products and to reduce unnecessary transfusion, it is important to ascertain whether transfusing critically ill but non-bleeding patients with a baseline INR < 2.5 is appropriate. Indeed, it is possible that there are some benefits, which are not measured by coagulation tests. Furthermore, these cut-offs are based on observational data, and might not truly reflect the efficacy of plasma transfusions, which could only be tested in a randomized controlled trial. Nonetheless, it seems obvious that a more restrictive transfusion strategy could considerably reduce the unnecessary use of plasma, which would allow for more appropriate resource utilization where truly needed.

This is the largest prospective observational study on plasma transfusions in critically ill children, both in terms of number of patients and in terms of PICUs. Worldwide enrollment enhances external validity. This study also avoided selection bias, as all but one eligible patients were enrolled. Definitive conclusions cannot be drawn but meaningful hypotheses have been generated. Our findings reveal certain very striking observations that suggest overuse of plasma in certain clinical contexts. The data will allow us to design a future RCT to evaluate these hypotheses.

Some limitations must be recognized. The design of our study does not permit comparison between patients transfused and not transfused with plasma. This was not the purpose of our study as data collection was limited only to patients who received plasma (prevalent cases) and not to the much larger group of patients who did not receive plasma. The patients in our study were sicker than those in a general PICU population, as our median PELOD-2 score and mortality rate were 7 (IQR 5-10) and 26.6%, respectively, compared to 4 (2-7) and 6.0% in a large PICU population (23). This may reflect the fact that plasma was given mainly to sicker patients. Although we enrolled virtually all patients admitted in the participating PICUs, there might have been a selection bias for centers themselves, as some sites with specific transfusion strategies might have been less keen to participate. The limited data collected did not include information on co-interventions, such as heparin, antithrombin, coagulation factor concentrates, vitamin K, or platelet administration. Finally, mortality was higher than anticipated in our patient cohort. It is therefore possible we underestimated the burden of rapidly fatal disease, as we did not measure ventilator-free days but only the length of mechanical ventilation.

This international observational study shows that non-bleeding patients represent more than half of the critically ill children receiving plasma transfusions. Commonly used coagulation tests are not sensitive to the effects of plasma transfusion for the majority of patients transfused. Studies assessing appropriate plasma transfusion strategies are urgently needed.

# Acknowledgments

We would like to thank all of the PlasmaTV investigators for their tremendous work. We would also like to thank the Plateforme de Recherche Clinique of the Department of Pediatrics, Geneva University Hospital, for their help with this study. We are also grateful to Alan Tinmouth, Daniel Levin, Douglas Willson, Kusum Menon and Neil Blumberg for their very helpful comments on the manuscript.

**PlasmaTV investigators**: **Australia**: Warwick Butt, Carmel Delzoppo, Kym Bain (Royal Childrens Hospital, Melbourne) ; Simon Erickson, Nathan Smalley (Princess Margaret Hospital for Children, Perth ; Tavey Dorofaeff , Debbie Long (Royal Childrens Hospital, Brisbane) ; Nathan Smalley, Greg Wiseman (Townsville Hospital, Townsville). **Belgium**: Stéphan Clément de Cléty, Caroline Berghe (Cliniques universitaires Saint-Luc, Brussels) ; Annick de Jaeger (Princess Elisabeth Children's University Hospital, Ghent) ; Pierre Demaret, Marc Trippaerts (CHC-CHR, Liège) ; Ariane Willems, Shancy Rooze (Hôpital universitaire des enfants Reine Fabiola, Brussels) ; Jozef De Dooy (Antwerp University Hospital, Edegem). **Canada**: Elaine Gilfoyle, Lynette Wohlgemuth (Alberta Children’s Hospital, Calgary, AB) ; Marisa Tucci, Mariana Dumitrascu (CHU Sainte-Justine, Montréal, QC) ; Davinia Withington, Julia Hickey (Montreal Children's Hospital, Montreal, QC) ; Karen Choong, Lois Sanders (McMaster Children's Hospital, Hamilton, ON) ; Gavin Morrison (IWK Health Centre, Halifax, NS) ; Janice Tijssen (Children's Hospital, London Health Sciences Centre, London, ON) ; David Wensley, Gordon Krahn (British Columbia Children's Hospital, Vancouver, BC) ; Marc-Andre Dugas, Louise Gosselin (Centre Mère Enfant Soleil, CHU de Québec, Québec, QC) ; Miriam Santschi (CHUS, Sherbrooke, QC). **Chile** : Bettina Von Dessauer, Nadia Ordenes (Hospital De Niños Roberto Del Río, Santiago). **Denmark**: Arash Afshari, Lasse Hoegh Andersen, Jens Christian Nilsson, Mathias Johansen, Anne-Mette Baek Jensen (Rigshospitalet, University of Copenhagen, Copenhagen). **Ecuador**: Santiago Campos Mino, Michelle Grunauer (Hospital de los Valles, Universidad San Francisco de Quito, Quito. **France**: Nicolas Joram (Hôpital mère enfant, Nantes) ; Nicolas Roullet-Renoleau (Hôpital Gatien de Clocheville, CHU Tours, Tours) ; Etienne Javouhey, Fleur Cour-Andlauer, Aurélie Portefaix (Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon) ; Olivier Brissaud, Julie Guichoux (Hôpital des Enfants, Bordeaux) ; Valérie Payen (CHU Grenoble, Grenoble) ; Pierre-Louis Léger (Hôpital Armand-Trousseau, Paris) ; Mickael Afanetti (Hopitaux Pédiatriques CHU Lenval, Nice) ; Guillaume Mortamet (Hopital Necker, Paris) ; Matthieu Maria (Hôpital d'Enfants CHRU de Nancy, Nancy) ; Audrey Breining (Hopitaux Universitaires de Strasbourg, Strasbourg) ; Pierre Tissieres (Hôpital Kremlin-Bicêtre, Paris) ; Aimée Dorkenoo (CHRU Lille, Lille) ; Anna Deho (Hopital Robert Debré, Paris). **Germany**: Harry Steinherr (Medizinische Hochschule Hannover, Hannover). **Greece**: Filippia Nikolaou (Athens Children Hospital P&A Kyriakou, Athens). **Italy**: Anna Camporesi (Children Hospital Vittore Buzzi, Milano) ; Federica Mario (Department of Women’s and Children’s Health, Padua). **Japan**: Tatsuya Kawasaki, Shinya Miura (Shizuoka Children's Hospital, Shizuoka City). **New Zealand**: John Beca, Miriam Rea, Claire Sherring, Tracey Bushell (Starship Children's Hospital, Auckland). **Norway**: Gunnar Bentsen (Oslo University Hospital – Rikshospitalet, Oslo). **Portugal**: Alexandra Dinis (Hospital Pediátrico – CHUC, Coimbra) ; Gabriela Pereira (UCIP Hospital Dona Estefânia, Lisbon) ; Marisa Vieira (Hospital de Santa Maria, Lisbon) ; Marta Moniz (Hospital Prof. Dr Fernando Fonseca, Amadora). **Saudi Arabia**: Saleh Alshehri (King Saud Medical City , Riyadh) ; Manal Alasnag, Ahmad Rajab (King Fahd Armed Forces Hospital, Jeddah). **Slovakia**: Maria Pisarcikova (DFN Kosice, Kosice). **Spain**: Iolanda Jordan (Hospital Sant Joan de Déu, Barcelona) ; Joan Balcells (Hospital Vall d'Hebron, Barcelona) ; Antonio Perez-Ferrer, Jesús de Vicente Sánchez, Marta Vazquez Moyano (La Paz University Hospital, Madrid) ; Antonio Morales Martinez (Malaga Regional University Hospitala, Malaga) ; Jesus Lopez-Herce, Maria Jose Solana (Hospital General Universitario Gregorio Marañón, Madrid) ; Jose Carlos Flores González (Puerta del Mar University Hospital, Cadiz) ; Maria Teresa Alonso (Hospital Virgen del Rocío, Sevilla) ; Manuel Nieto Faza (Hospital Universitario Cruces, Bilbao). **Switzlerand**: Marie-Hélène Perez, Vivianne Amiet (CHUV, Lausanne) ; Carsten Doell (Kinderspital Zürich, Zürich) ; Alice Bordessoule (Geneva University Hospital, Geneva). **The Netherlands**: Suzan Cochius-den Otter, Berber Kapitein (Erasmus MC - Sophia Children's Hospital, Rotterdam) ; Martin Kneyber (Beatrix Children's Hospital, Groningen). **United Kingdom**: Joe Brierley, Vanessa Rea, Stephen McKeever (Great Ormond Street, London) ; Andrea Kelleher (Royal Brompton Hospital, London) ; Barney Scholefield, Anke Top, Nicola Kelly, Satnam Virdee (Birmingham Children's Hospital, Birmingham) ; Peter Davis, Susan George (Bristol Royal Hospital for Children, Bristol) ; Kay C Hawkins, Philip Hudnott, Victoria Brown (Royal Manchester Children's Hospital, Manchester) ; Kim Sykes (University Hospital Southampton, Southampton) ; Richard Levin, Isobel MacLeod (Yorkhill Childrens Hospital, Glasgow) ; Marie Horan, Petr Jirasek (Alder Hey Children's hospital, Liverpool) ; David Inwald, Amina Abdulla, Sophie Raghunanan (Imperial College Healthcare, London) ; Bob Taylor (Royal Belfast Hospital for Sick Children, Belfast) ; Alison Shefler, Hannah Sparkes (Oxford University Hospitals, Oxford). **USA** : Sheila Hanson, Katherine Woods, David Triscari, Kathy Murkowski (Children's Hospital of Wisconsin, Milwaukee, WI) ; Caroline Ozment (Duke University, Durham, NC) ; Marie Steiner, Dan Nerheim, Amanda Galster (University of Minneapolis, Minneapolis, MN) ; Renee Higgerson, LeeAnn Christie (Dell Children's Medical Center, Austin, TX) ; Phil Spinella, Daniel Martin, Liz Rourke (Washington University in St. Louis, Saint Louis, MO) ; Jennifer Muszynski, Lisa Steele, (Nationwide Children's Hospital, Columbus, OH) ; Samuel Ajizian, Michael McCrory (Wake Forest School of Medicine, Winston-Salem, NC) ; Kevin O'Brien, Christopher Babbitt, Erin Felkel, Glenn Levine (Miller Children's Hospital Long Beach, Long Beach, CA) ; Edward J Truemper, Machelle Zink (Children's Hospital and Medical Center, Omaha, NE) ; Marianne Nellis (NYPH - Weill Cornell Medical College, New York, NY) ; Neal J Thomas, Debbie Spear (Penn State Hershey Children's Hospital, Hershey, PA) ; Barry Markovitz, Jeff Terry, Rica Morzov (Children's Hospital Los Angeles, Los Angeles, CA) ; Vicki Montgomery, Andrew Michael, Melissa Thomas (University of Louisville and Kosair Children's Hospital, Louisville, KY) ; Marcy Singleton, Dean Jarvis, Sholeen Nett (Dartmouth Hitchcock Medical Center, Lebanon, NH) ; Douglas Willson, Michelle Hoot (Virginia Commonwealth University, Richmond, VA) ; Melania Bembea, Alvin Yiu (Johns Hopkins University, Baltimore, MD) ; David McKinley, Elizabeth Scarlett, Jennifer Sankey, Minal Parikh (Geisinger, Danville, PA) ; E. Vincent S. Faustino (Yale School of Medicine, New Haven, CT) ; Kelly Michelson, Jay Rilinger, Laura Campbell (Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL); Shira Gertz (Hackensack University Medical Center, Hackensack, NJ) ; Jill M. Cholette (University of Rochester, Rochester, NY) ; Asumthia Jeyapalan (Holtz Children's Hospital-Jackson Memorial Hospital, Miami, FL) ; Margaret Parker (Stony Brook University, Stony Brook, NY) ; Scot Bateman, Amanda Johnson (UMass Memorial Children's Medical Center, Worcester, MA).

# References

1. United States Department of Health and Human Services. 2011 National Blood Collection and Utilization Survey Report; 2013.

2. Puetz J, Witmer C, Huang YS, Raffini L. Widespread use of fresh frozen plasma in US children's hospitals despite limited evidence demonstrating a beneficial effect. *J Pediatr* 2012; 160: 210-215 e211.

3. Djoudi R. [Transfusion of plasma: products-indications]. *Transfus Clin Biol* 2013; 20: 47-54.

4. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D, Yates S, Williamson LM. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. *Br J Haematol* 2004; 126: 11-28.

5. Liumbruno G, Bennardello F, Lattanzio A, Piccoli P, Rossetti G. Recommendations for the transfusion of plasma and platelets. *Blood Transfus* 2009; 7: 132-150.

6. Holcomb JB, Wade CE, Michalek JE, Chisholm GB, Zarzabal LA, Schreiber Ma, Gonzalez Ea, Pomper GJ, Perkins JG, Spinella PC, Williams KL, Park MS. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. *Ann Surg* 2008; 248: 447-458.

7. Sarani B, Dunkman WJ, Dean L, Sonnad S, Rohrbach JI, Gracias VH. Transfusion of fresh frozen plasma in critically ill surgical patients is associated with an increased risk of infection. *Crit Care Med* 2008; 36: 1114-1118.

8. Karam O, Lacroix J, Robitaille N, Rimensberger PC, Tucci M. Association between plasma transfusions and clinical outcome in critically ill children: a prospective observational study. *Vox Sang* 2013; 104: 342-349.

9. Dara SI, Rana R, Afessa B, Moore SB, Gajic O. Fresh frozen plasma transfusion in critically ill medical patients with coagulopathy. *Crit Care Med* 2005; 33: 2667-2671.

10. Khan H, Belsher J, Yilmaz M, Afessa B, Winters JL, Moore SB, Hubmayr RD, Gajic O. Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. *Chest* 2007; 131: 1308-1314.

11. Watson GA, Sperry JL, Rosengart MR, Minei JP, Harbrecht BG, Moore EE, Cuschieri J, Maier RV, Billiar TR, Peitzman AB. Fresh frozen plasma is independently associated with a higher risk of multiple organ failure and acute respiratory distress syndrome. *J Trauma* 2009; 67: 221-227; discussion 228-230.

12. Church GD, Matthay MA, Liu K, Milet M, Flori HR. Blood product transfusions and clinical outcomes in pediatric patients with acute lung injury. *Pediatr Crit Care Med* 2009; 10: 297-302.

13. Abdel-Wahab OI, Healy B, Dzik WH. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. *Transfusion* 2006; 46: 1279-1285.

14. Holland LL, Brooks JP. Toward rational fresh frozen plasma transfusion: The effect of plasma transfusion on coagulation test results. *Am J Clin Pathol* 2006; 126: 133-139.

15. Stanworth SJ, Grant-Casey J, Lowe D, Laffan M, New H, Murphy MF, Allard S. The use of fresh-frozen plasma in England: high levels of inappropriate use in adults and children. *Transfusion* 2011; 51: 62-70.

16. Dzik W, Rao A. Why do physicians request fresh frozen plasma? *Transfusion* 2004; 44: 1393-1394.

17. Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. *Transfusion* 2005; 45: 1413-1425.

18. Lauzier F, Cook D, Griffith L, Upton J, Crowther M. Fresh frozen plasma transfusion in critically ill patients. *Crit Care Med* 2007; 35: 1655-1659.

19. Karam O, Tucci M, Lacroix J, Rimensberger PC. International survey on plasma transfusion practices in critically ill children. *Transfusion* 2014; 54: 1125-1132.

20. Karam O, Tucci M, Combescure C, Lacroix J, Rimensberger PC. Plasma transfusion strategies for critically ill patients. *Cochrane Database Syst Rev* 2013; 12: CD010654.

21. Arnold DM, Donahoe L, Clarke FJ, Tkaczyk AJ, Heels-Ansdell D, Zytaruk N, Cook R, Webert KE, McDonald E, Cook DJ. Bleeding during critical illness: a prospective cohort study using a new measurement tool. *Clin Invest Med* 2007; 30: E93-102.

22. Labarinas S, Arni D, Karam O. Plasma in the PICU: why and when should we transfuse? *Annals of intensive care* 2013; 3: 1-1.

23. Leteurtre S, Duhamel A, Salleron J, Grandbastien B, Lacroix J, Leclerc F, Groupe Francophone de Reanimation et d'Urgences Pediatriques. PELOD-2: an update of the PEdiatric logistic organ dysfunction score. *Crit Care Med* 2013; 41: 1761-1773.

24. Leteurtre S, Duhamel A, Grandbastien B, Proulx F, Cotting J, Gottesman R, Joffe A, Wagner B, Hubert P, Martinot A, Lacroix J, Leclerc F. Daily estimation of the severity of multiple organ dysfunction syndrome in critically ill children. *CMAJ* 2010; 182: 1181-1187.

25. Kor DJ, Stubbs JR, Gajic O. Perioperative coagulation management--fresh frozen plasma. *Best Pract Res Clin Anaesthesiol* 2010; 24: 51-64.

26. Williamson LM, Devine DV. Challenges in the management of the blood supply. *Lancet* 2013; 381: 1866-1875.

# Tables

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table 1**: Demographic data according to primary indication for plasma transfusion | | | | | | |
|  | Critical bleeding  (n=99) | Minor bleeding  (n=94) | Planned procedure  (n=52) | High risk of post-operative bleeding  (n=47) | No bleeding, no procedure  (n=151) | p |
| Gender [male], n (%) | 40 (40%) | 39 (41%) | 20 (38%) | 15 (32%) | 75 (50%) | 0.21 |
| Age [years], median (IQR) | 4.0 (0.25-11.1) | 1.7 (0.25-7.6) | 2.0 (0.5-6.1) | 0.5 (0.1-1.9) | 0.5 (0.1-4.4) | <0.001 |
| Weight [kg], median (IQR) | 15.1 (4.7-35.0) | 9.7 (4.5-20.0) | 12.0 (6.0-27.8) | 6.1 (3.6-11.9) | 6.9 (3.5-17.5) | 0.001 |
| Reasons for PICU admission\* (n, %) | |  |  |  |  |  |
| respiratory | 35 (35%) | 21 (22%) | 18 (35%) | 8 (17%) | 61 (40%) | 0.006 |
| septic shock | 5 (5%) | 9 (10%) | 11 (21%) | 1 (2%) | 39 (26%) | <0.001 |
| hemorrhagic shock | 26 (26%) | 2 (2%) | 4 (8%) | 0 (0%) | 4 (3%) | <0.001 |
| other shock | 9 (9%) | 4 (4%) | 4 (8%) | 6 (13%) | 11 (7%) | 0.46 |
| trauma | 19 (19%) | 3 (3%) | 1 (2%) | 0 (0%) | 6 (4%) | <0.001 |
| traumatic brain injury | 15 (15%) | 1 (1%) | 2 (4%) | 0 (0%) | 8 (5%) | <0.001 |
| burn | 0 (0%) | 1 (1%) | 1 (2%) | 1 (2%) | 2 (1%) | 0.75 |
| cardiac surgery (bypass) | 30 (30%) | 47 (50%) | 1 (2%) | 19 (40%) | 36 (24%) | <0.001 |
| cardiac surgery (no bypass) | 0 (0%) | 3 (3%) | 1 (2%) | 7 (15%) | 6 (4%) | <0.001 |
| cardiac non-surgical | 7 (7%) | 10 (11%) | 7 (14%) | 3 (6%) | 23 (15%) | 0.24 |
| emergency surgery | 29 (29%) | 2 (2%) | 6 (12%) | 9 (19%) | 13 (9%) | <0.001 |
| elective surgery | 16 (16%) | 47 (50%) | 3 (6%) | 22 (47%) | 19 (13%) | <0.001 |
| seizure | 5 (5%) | 2 (2%) | 4 (8%) | 1 (2%) | 11 (7%) | 0.32 |
| encephalopathy | 6 (6%) | 5 (5%) | 3 (6%) | 0 (0%) | 9 (6%) | 0.57 |
| meningitis | 2 (2%) | 0 (0%) | 2 (4%) | 0 (0%) | 5 (3%) | 0.29 |
| renal failure | 8 (8%) | 10 (11%) | 10 (19%) | 1 (2%) | 16 (11%) | 0.07 |
| hepatic failure | 10 (10%) | 5 (5%) | 11 (21%) | 1 (2%) | 18 (12%) | 0.01 |
| post-operative liver transplantation | 2 (2%) | 0 (0%) | 2 (4%) | 4 (9%) | 3 (2%) | 0.04 |
| other reason† | 11 (11%) | 2 (2%) | 8 (15%) | 9 (19%) | 17 (11%) | 0.24 |
| Severity at inclusion (plasma transfusion) (median, IQR) | | |  |  |  |  |
| PELOD-2 score | 8 (6-11) | 7 (5-8) | 7 (4-11) | 7 (5-9) | 7 (5-10) | 0.05 |
| Worst lactate | 3.2 (1.6-5.3) | 2.4 (1.7-4.1) | 2.2 (1.2-4.9) | 2.7 (1.9-5.4) | 2.1 (1.4-5.1) | 0.54 |
| Support (n, %) |  |  |  |  |  |  |
| Mechanical ventilation | 87 (88%) | 82 (87%) | 38 (73%) | 42 (89%) | 122 (81%) | .08 |
| ECLS | 12 (12%) | 7 (7%) | 1 (2%) | 11 (23%) | 17 (11%) | 0.1 |
| CRRT | 5 (5%) | 7 (7%) | 6 (12%) | 5 (11%) | 12 (8%) | 0.63 |
| MARS | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | - |
| Intermittent dialysis | 1 (1%) | 1 (1%) | 1 (2%) | 0 (0%) | 2 (1%) | 0.92 |

\*Some patients had more than one reason for admission.

†The main other reasons for admission were oncologic-hematologic disease (19 patients), neurosurgery (5 patients), and metabolic disorders (4 patients).

CRRT: Continuous Renal Replacement Therapy; ECLS: Extracorporeal Life Support; MARS: Molecular Adsorbent Recirculating System; PELOD-2 score: Pediatric Logistic Organ Dysfunction 2 score (23); PICU: Pediatric Intensive Care Unit.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table 2**: Patient outcomes according to primary indication for plasma transfusion | | | | | | |
|  | Critical bleeding  (n=99) | Minor bleeding  (n=94) | Planned procedure  (n=52) | High risk of post-operative bleeding  (n=47) | No bleeding, no procedure  (n=151) | p |
| PELOD-2 score |  |  |  |  |  |  |
| Day 2\* (n=402) | 8 (5-10) | 6 (5-8) | 8 (4-11) | 8 (5-9) | 8 (5-10) | 0.37 |
| Day 5\* (n=296) | 7 (5-9) | 6 (3-9) | 8 (4-10) | 7 (4-10) | 8 (4-10) | 0.43 |
| Day 8\* (n=227) | 6 (4-9) | 5 (3-9) | 8 (4-10) | 7 (5-9) | 6 (3-9) | 0.69 |
| Day 12\* (n=162) | 6 (3-7) | 6 (2-9) | 7 (3-10) | 6 (3-8) | 7 (3-9) | 0.79 |
| Duration of mechanical ventilation (days) | 5 (1-15) | 2 (1:8) | 9 (2-25) | 7 (3-13) | 6 (2-17) | 0.20 |
| PICU length of stay (days) | 11 (3-23) | 7 (3-14) | 18 (5-32) | 11 (6-25) | 12 (4-26) | 0.46 |
| Mortality, n (%) | 34 (35%) | 14 (16%) | 16 (32%) | 9 (19%) | 46 (31%) | 0.01 |

Results are provided as median and interquartile range (IQR), except for mortality.

\* Days after the first plasma transfusion.

PELOD-2 score: Pediatric Logistic Organ Dysfunction 2 score (23); PICU: Pediatric Intensive Care Unit.

# Figure legends

**Figure 1**: Proportion of the different primary indications to plasma transfusion. The indications were categorized as *critical bleeding* (massive bleeding, bleeding in specific sites, or bleeding requiring a surgical intervention or drainage, in red), *minor bleeding* (in orange), *preparation for surgery or procedures* (in yellow), *at high risk of post-operative bleeding* (in gray), and *no bleeding, no planned procedure* (in green).

**Figure 2**: Changes in International Normalized Ratio (INR, panel A) and activated Partial Thromboplastin Time (aPTT, panel B) after plasma transfusion, according to the indications for transfusion: *critical bleeding* (in red), *minor bleeding* (in orange), *preparation for surgery or procedures* (in yellow), *at high risk of post-operative bleeding* (in gray), and *no bleeding, no planned procedure* (in green). The median INR change was -0.2 (IQR -0.4 to 0, n=281 pairs of tests) and the median aPTT change was -5 (IQR -17 to 2). Mild outliers (< 1.5 \* IQR) and extreme outliers (> 1.5 \* IQR) are marked with a circle (O) and asterisk (\*) on the boxplot.

**Figure 3**: Boxplot of the changes in International Normalized Ratio (INR, panel A) and activated Partial Thromboplastin Time (aPTT, panel B) after plasma transfusion, according to the coagulation test prior to transfusion (n=281 and n=360 pairs of INR and aPTT, respectively). Mild outliers (< 1.5 \* IQR) and extreme outliers (> 1.5 \* IQR) are marked with a circle (O) and asterisk (\*) on the boxplot.

**Figure 4**: Boxplot of the changes in International Normalized Ratio (INR, panel A) and activated Partial Thromboplastin Time (aPTT, panel B) after plasma transfusion, according to the dose of plasma transfusion in ml/kg and according to the baseline coagulation test (n=281 and n=360 pairs of INR and aPTT, respectively). Mild outliers (< 1.5 \* IQR) and extreme outliers (> 1.5 \* IQR) are marked with a circle (O) and asterisk (\*) on the boxplot.